Terms: = Gastric cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Prognosis
18 results:
1. The Meaningful Function of the Emerging Clinical Targets-lncRNA MEG3 in gastric cancer.
Zhang Y; Wang Y; Jiang Y; Bai H; Wen Y
Curr Pharm Des; 2023; 29(28):2204-2212. PubMed ID: 37846125
[TBL] [Abstract] [Full Text] [Related]
2. Helicobacter pylori-induced NAT10 stabilizes mdm2 mRNA via RNA acetylation to facilitate gastric cancer progression.
Deng M; Zhang L; Zheng W; Chen J; Du N; Li M; Chen W; Huang Y; Zeng N; Song Y; Chen Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):9. PubMed ID: 36609449
[TBL] [Abstract] [Full Text] [Related]
3. High Expression of UPK3A Promotes the Progression of gastric cancer Cells by Inactivating p53 Pathway.
Xu D; Guo J; Xu H
Anal Cell Pathol (Amst); 2022; 2022():6897561. PubMed ID: 35774082
[TBL] [Abstract] [Full Text] [Related]
4. CircMCTP2 (has-circ-0000658) facilitates the proliferation and metastasis of bladder carcinoma through modulating the miR-498/murine double minute-2 axis.
Gu Q; Hou W; Shi L; Zhu Z; Liu H; He X
Bioengineered; 2022 Apr; 13(4):10734-10748. PubMed ID: 35475453
[TBL] [Abstract] [Full Text] [Related]
5. ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications.
El Jabbour T; Misyura M; Cowzer D; Zimmermann M; Rimkunas V; Marra A; Derakhshan F; Selenica P; Parilla M; Setton JS; Ceyhan-Birsoy O; Kemel Y; Catchings A; Ranganathan M; Ku GY; Janjigian YY; Zinda M; Koehler M; Stadler Z; Shia J; Reis-Filho JS; Mandelker D
J Natl Cancer Inst; 2022 May; 114(5):761-770. PubMed ID: 35078243
[TBL] [Abstract] [Full Text] [Related]
6. Down-regulated MicroRNAs in gastric Carcinoma May Be Targets for Therapeutic Intervention and Replacement Therapy.
Weidle UH; Birzele F; Auslaender S; Brinkmann U
Anticancer Res; 2021 Sep; 41(9):4185-4202. PubMed ID: 34475038
[TBL] [Abstract] [Full Text] [Related]
7. MDM4 as a Prognostic Factor for Patients With gastric cancer With Low Expression of p53.
Zhang X; Yamamoto Y; Wang X; Sato M; Imanishi M; Sugaya A; Hirose M; Endo S; Moriwaki T; Yamato K; Hyodo I
Anticancer Res; 2021 Mar; 41(3):1475-1483. PubMed ID: 33788740
[TBL] [Abstract] [Full Text] [Related]
8. E2F1-activated SPIN1 promotes tumor growth via a mdm2-p21-E2F1 feedback loop in gastric cancer.
Lv BB; Ma RR; Chen X; Zhang GH; Song L; Wang SX; Wang YW; Liu HT; Gao P
Mol Oncol; 2020 Oct; 14(10):2629-2645. PubMed ID: 32767629
[TBL] [Abstract] [Full Text] [Related]
9. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
[TBL] [Abstract] [Full Text] [Related]
10. HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with mdm2 and confers 5-FU resistance by a p53-dependent pathway.
Han Y; Song C; Wang J; Tang H; Peng Z; Lu S
Mol Carcinog; 2018 Jun; 57(6):722-734. PubMed ID: 29436749
[TBL] [Abstract] [Full Text] [Related]
11. Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Nakamura H; Dobashi Y
Mod Pathol; 2015 Jun; 28(6):861-71. PubMed ID: 25743022
[TBL] [Abstract] [Full Text] [Related]
12. Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
Wang N; She J; Liu W; Shi J; Yang Q; Shi B; Hou P
Cell Cycle; 2015; 14(5):732-43. PubMed ID: 25590580
[TBL] [Abstract] [Full Text] [Related]
13. UBTD1 induces cellular senescence through an UBTD1-mdm2/p53 positive feedback loop.
Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
[TBL] [Abstract] [Full Text] [Related]
14. PICT1 regulates TP53 via RPL11 and is involved in gastric cancer progression.
Uchi R; Kogo R; Kawahara K; Sudo T; Yokobori T; Eguchi H; Sugimachi K; Maehama T; Mori M; Suzuki A; Komune S; Mimori K
Br J Cancer; 2013 Oct; 109(8):2199-206. PubMed ID: 24045667
[TBL] [Abstract] [Full Text] [Related]
15. A functional polymorphism T309G in mdm2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients.
Pan X; Li Y; Feng J; Wang X; Hao B; Shi R; Zhang G
BMC Cancer; 2013 Mar; 13():126. PubMed ID: 23506213
[TBL] [Abstract] [Full Text] [Related]
16. mdm2 is a useful prognostic biomarker for resectable gastric cancer.
Ye Y; Li X; Yang J; Miao S; Wang S; Chen Y; Xia X; Wu X; Zhang J; Zhou Y; He S; Tan Y; Qiang F; Li G; Røe OD; Zhou J
Cancer Sci; 2013 May; 104(5):590-8. PubMed ID: 23347235
[TBL] [Abstract] [Full Text] [Related]
17. Study of the Murine Double Minute 2 status in patients with gastric and colorectal carcinomas and its correlation with prognostic factors.
Sepideh S; Mohammadreza JN; Ali D; Gholamreza TP; Samira G
Indian J Pathol Microbiol; 2012; 55(2):192-5. PubMed ID: 22771642
[TBL] [Abstract] [Full Text] [Related]
18. mdm2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
[TBL] [Abstract] [Full Text] [Related]
